Huiying Sun

Huiying Sun

Auto-generated profile, based on publicly available information

Huiying Sun

Departments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
MNMonique B. Nilsson
Monique B. Nilsson
HSHuiying Sun
Huiying Sun
JRJacqulyne Robichaux
Jacqulyne Robichaux
MPMatthias Pfeifer
Matthias Pfeifer
UMUltan McDermott
Ultan McDermott
JHJohn V. Heymach
John V. Heymach
YAP and FOXM1 are mediators of EGFR inhibitor resistance, and spindle proteins are therapeutic targets for this multidrug-resistant phenotype.

8 November 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MNMonique B. Nilsson
Monique B. Nilsson
HSHuiying Sun
Huiying Sun
LDLixia Diao
Lixia Diao
PTPan Tong
Pan Tong
DLDiane Liu
Diane Liu
JHJohn V. Heymach
John V. Heymach
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance mediated by T790M-independent mechanisms remains a major challenge in the treatment of non–small cell lung cancer (NSCLC). We identified a targetable mechanism of EGFR inhibitor resistance whereby stress hormones activate β2-adrenergic receptors (β2-ARs) on NSCLC cells, which cooperatively signal with mutant EGFR, resulting in the inactivation of the tumor suppressor, liver kinase B1 (LKB1), and subsequently induce interleukin-6 (IL-6) expression. We show that stress and β2-AR activation promote tumor growth and EGFR inhibitor resistance, which can be abrogated with β-blockers or IL-6 inhibition. IL-6 was associated with a worse outcome in EGFR TKI–treated NSCLC patients, and β-blocker use was associated with lower IL-6 concentrations and improved benefit from EGFR inhibitors. These findings provide evidence that chronic stress hormones promote EGFR TKI resistance via β2-AR signaling by an LKB1/CREB (cyclic adenosine 3′,5′-monophosphate response element–binding protein)/IL-6–dependent mechanism and suggest that combinations of β-blockers with EGFR TKIs merit further investigation as a strategy to abrogate resistance.